These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21385169)

  • 61. High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy.
    Jackson GH; Angus B; Carey PJ; Finney RD; Galloway MJ; Goff DK; Haynes A; Lennard AL; Leonard RC; McQuaker IG; Proctor SJ; Russell N; Windebank K; Taylor PR;
    Leuk Lymphoma; 2000 May; 37(5-6):561-70. PubMed ID: 11042516
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.
    Moskowitz CH; Nimer SD; Zelenetz AD; Trippett T; Hedrick EE; Filippa DA; Louie D; Gonzales M; Walits J; Coady-Lyons N; Qin J; Frank R; Bertino JR; Goy A; Noy A; O'Brien JP; Straus D; Portlock CS; Yahalom J
    Blood; 2001 Feb; 97(3):616-23. PubMed ID: 11157476
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
    Castagna L; Magagnoli M; Balzarotti M; Sarina B; Siracusano L; Nozza A; Todisco E; Bramanti S; Mazza R; Russo F; Timofeeva I; Santoro A
    Am J Hematol; 2007 Feb; 82(2):122-7. PubMed ID: 17019686
    [TBL] [Abstract][Full Text] [Related]  

  • 64. ABVD Without Radiation for Newly Diagnosed Pediatric and Young Adult Patients With Hodgkin Lymphoma: A Single Center Retrospective Analysis of 28 Consecutive Patients.
    Stieglitz E; Dinh T; Phelps AS; Pampaloni MH; Olshen AB; Robbins E
    J Pediatr Hematol Oncol; 2018 May; 40(4):290-294. PubMed ID: 29432308
    [TBL] [Abstract][Full Text] [Related]  

  • 65. FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):7. PubMed ID: 24870873
    [No Abstract]   [Full Text] [Related]  

  • 66. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors.
    Boleti E; Mead GM
    Ann Oncol; 2007 Feb; 18(2):376-80. PubMed ID: 17071938
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
    Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
    Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma.
    Pocali B; De Simone M; Annunziata M; Palmieri S; D'Amico MR; Copia C; Viola A; Mele G; Schiavone EM; Ferrara F
    Leuk Lymphoma; 2004 Aug; 45(8):1605-9. PubMed ID: 15370212
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma.
    Ibrahim D; Smith MR; Varterasian M; Karanes C; Millenson M; Yeslow G; Pemberton P; Lai P; Abrams J; Al-Katib A
    Leuk Lymphoma; 2004 Oct; 45(10):2079-84. PubMed ID: 15370253
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization.
    Menzel H; Müller A; Von Schilling C; Licht T; Peschel C; Keller U
    Leuk Lymphoma; 2008 Jul; 49(7):1337-44. PubMed ID: 18604723
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
    Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
    Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma.
    Kim SK; Song MK; Chung JS; Shin HJ
    Int J Hematol; 2013 Nov; 98(5):543-8. PubMed ID: 24068657
    [TBL] [Abstract][Full Text] [Related]  

  • 73. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
    Persky DO; Moskowitz CH; Filatov A; Saxena R; Cui H; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):35-40. PubMed ID: 19701081
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).
    Joyce RM; Regan M; Ottaway J; Umiel T; Tetreault JC; Levine J; McDermott D; Hurley D; Giallombardo N; Smith T; Lamontagne D; Uhl L; Avigan D
    Ann Oncol; 2003; 14 Suppl 1():i21-7. PubMed ID: 12736227
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.
    Gisselbrecht C; Lepage E; Molina T; Quesnel B; Fillet G; Lederlin P; Coiffier B; Tilly H; Gabarre J; Guilmin F; Hermine O; Reyes F;
    J Clin Oncol; 2002 May; 20(10):2472-9. PubMed ID: 12011124
    [TBL] [Abstract][Full Text] [Related]  

  • 76. IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
    Abali H; Oyan B; Koc Y; Kars A; Barista I; Uner A; Turker A; Demirkazik F; Tekin F; Tekuzman G; Kansu E
    Am J Clin Oncol; 2005 Jun; 28(3):264-9. PubMed ID: 15923799
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Eom HS; Kim JS; Lee YY; Oh SJ; Lee DH; Suh C
    Invest New Drugs; 2011 Feb; 29(1):154-60. PubMed ID: 19756371
    [TBL] [Abstract][Full Text] [Related]  

  • 78. IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas.
    Park BB; Kim WS; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Jung CW; Park YS; Im YH; Kang WK; Ko YH; Lee MH; Park K
    Leuk Lymphoma; 2005 Dec; 46(12):1743-8. PubMed ID: 16263576
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.
    Zinzani PL; Broccoli A; Gioia DM; Castagnoli A; Ciccone G; Evangelista A; Santoro A; Ricardi U; Bonfichi M; Brusamolino E; Rossi G; Anastasia A; Zaja F; Vitolo U; Pavone V; Pulsoni A; Rigacci L; Gaidano G; Stelitano C; Salvi F; Rusconi C; Tani M; Freilone R; Pregno P; Borsatti E; Sacchetti GM; Argnani L; Levis A
    J Clin Oncol; 2016 Apr; 34(12):1376-85. PubMed ID: 26884559
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK).
    Proctor SJ; Jackson GH; Lennard A; Angus B; Wood K; Lucraft HL; White J; Windebank K; Taylor PR;
    Ann Oncol; 2003; 14 Suppl 1():i47-50. PubMed ID: 12736232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.